Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 18, 2023 at 10:01 pm
Share
Oncotelic Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 6.76 million compared to net income of USD 16.01 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to basic earnings per share from continuing operations of USD 0.04 a year ago.
For the six months, net loss was USD 7.28 million compared to net income of USD 11.16 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to basic earnings per share from continuing operations of USD 0.03 a year ago.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâs Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.